«In distinct contrast to the situation in the U.S., Australia's Pharmaceutical Benefits Advisory Committee (PBAC) recently recommended two highly
effective sofosbuvir - based regimens for Pharmaceutical Benefits Scheme (PBS) listing, without drug use or disease stage - related restrictions,» said co-author and professor Greg Dore of the Kirby Institute.
Not exact matches
Most states violate federal Medicaid law because they deny coverage for
sofosbuvir, a new and highly
effective treatment to cure hepatitis C, according to Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV / Viral Hepatitis Coinfection Program.
Results presented today at The International Liver Congress ™ 2015 show that the
sofosbuvir (SOF) / daclatasvir (DCV) treatment combination is
effective amongst hepatitis C virus (HCV) genotype - 1 mono - infected patients.
«
Sofosbuvir / daclatasvir combination
effective treatment for difficult - to - treat hep C patients.»
The drug works by inhibiting replication of the hepatitis C virus; researchers noted that both hepatitis C and Zika belong to the same viral family and bore strong structural similarities that could make
sofosbuvir effective against the latter.